Home  »  Ipo Review  »  Biocon Ipo

Let’s have a detailed review of the company and analytics of the Biocon Biologics Limited IPO release date, IPO offer price, subscription, Biocon IPO allotment, grey market price and other details like the company’s background, its financial positions, its promoters and other related things.Stock Broker Complaints

Biocon IPO Review & Ratings

IPO Ratings & Review
Criteria Ratings
Industry Sentiments 7.4/10
Industry Ranking 7.1/10
Company Background 8.2/10
Company Reputation 7.7/10
Competitive Edge 7.2/10
Financial Statements 8.0/10
Popularity Index 7.6/10
Promoters Reputation 8.0/10
Retail Appetite 7.5/10
Top Brokers Review 8.1/10
Overall Ratings 7.5/10
Star Ratings ★★★★☆

Summary of BIOCON IPO


Established in 1978, Biocon Biologics Ltd. is India’s largest biotechnology company. Biocon and its two subsidiary companies, Syngene International Pvt. Ltd. and Clinigene International Pvt. Ltd. form a fully integrated biotechnology enterprise, specialising in biopharmaceuticals, custom research, clinical research and enzymes.

Biocon Biologic was carved out as subsidiary, with research and development, manufacturing and distribution functions of biosimiars in April last year. This was done to create a vertically integrated biologics company, with an intention to unlock value and give investors a pure-play investment opportunity in biologics.

Financial Analysis, as per the Restated Financial Statements

  • Analysts estimate the valuation of Biocon Biologics at more than 10 times, with anticipated revenues of Rs.2,000 crore in FY20. Biocon’s revenue at the end of FY19 was at Rs.5,658.8 crore, of which 27 percent or Rs.1,528 crore was contributed by the biologics division.
  • Biocon Biologics alone now constitutes about 60 percent of parent Biocon’s market capitalisation of around $5 billion. The contract research subsidiary Syngene, excluding minority shareholders stake, is valued at $1.4 billion and the residuary business of Biocon business, that includes small molecules and domestic formulations, is now valued at $600 million.

The Promoter of this company is [●]. The lead managers to the issue are DSP Merrill Lynch Ltd. and Kotak Mahindra Capital Company Ltd, HSBC Securities & Capital Markets (India) Pvt. Ltd. The Registrar to this issue is [●].

BIOCON IPO Dates / Launch Date

The opening and the closing date of BIOCON IPO is not known yet.

BIOCON IPO Subscription 

Day / Date QIB NII RII Total Subscription
1st Day – 
2nd Day – 
3rd Day – 
4th Day – 
Shares Offered or Net Issue

The shares subscribed by the public will be updated here.

BIOCON IPO Allotment Status

Here, you can find the Allotment Status of this IPO. Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment status is not yet disclosed.

BIOCON IPO Listing Date

Find the dates below on basis of allotment, refund, listing and more:

Basis of Allotment Finalization
Refunds Initiation
Credit of Shares to Demat Account
Share Listing Date

BIOCON IPO Price Band / Cash Price

The face value of each share is Rs.5, and the cash price of the IPO is [●]. 


This Initial Public Issue of 10 million equity shares of Rs.5 each for cash at a price of Rs.270 to Rs.315 per equity share aggregating to Rs.[●] Lakhs.

BIOCON IPO Share Offering

Fresh Issue: The Fresh Issue of 110 million equity shares of the face value of Rs.5 each in a price band of Rs.270 to Rs.315.

Biocon Biologics Limited – Company Overview

Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

They have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

BIOCON Global Scale

Biocon has created large-scale fermentation capabilities to support manufacturing of APIs like statins and immunosuppressants. They also built one of India’s largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices. They continue to invest in expanding their manufacturing capacities to address the growing market need.

Biocon’s insulin manufacturing and R&D facility set up in Malaysia with an investment of USD 300 million is the largest integrated insulins facility in Asia. This is the largest foreign investment in biotechnology in Malaysia and reflects their commitment to serve patients in different parts of the world.

BIOCON – Quality Assurance

Biocon’s state-of-the-art manufacturing facilities are qualified by various regulatory agencies from developed and emerging markets. With an unwavering commitment to quality assurance and stringent quality controls, Biocon is on a mission to go beyond compliance and achieve global standards of excellence.

A well-trained Quality team works round the clock to monitor every step of the development and manufacturing process to ensure that each and every product manufactured and distributed by them complies with all internationally accepted good practices and standards of quality, purity, efficacy and safety.

Biocon’s business is organized into the following reporting segments:
a) Small Molecules API & Generic Formulations
b) Biologics – Biosimilars (Insulins, MAbs & other Biologics) & Novel Biologics
c) Branded Formulations (currently India & UAE)
d) Research Services (Syngene)

BIOCON – Brand Formulation

Biocon’s Branded Formulations business focuses on regional markets and is currently operational in India and the UAE. This business has focused on specialty brands in critical therapies and enabled Biocon to emerge as a biologics-led healthcare company offering affordable and differentiated medicines of world-class quality to thousands of patients in India and UAE.

Their Branded Formulations India business has enabled them to carve out a premium niche for themselves as a biologics-led, specialty products company focused on chronic therapy areas. They are the largest Indian insulins company and one of the leading oncology companies in the country. Some of their key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab), KRABEVA® (Bevacizumab) and ALZUMAb™ (Itolizumab).

BIOCON Research Services

Their listed subsidiary, Syngene International Limited, is India’s largest Contract Research Organization (CRO). Syngene started as India’s first CRO and has over the years built a reputation as an end-to-end drug discovery and development services provider for novel molecular entities to the global life sciences sector.

It provides integrated discovery, development and manufacturing services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides.

Syngene brings together a state-of-the-art infrastructure spread across 1.4 mn sq ft and a pool of over 4,000 scientists, to help R&D focused organizations achieve better R&D efficiency and reduce development time.

BIOCON Limited: Business strategies

  • They have created a highly cross-functional matrix focused on products, processes and people to reliably and consistently develop and deliver differentiated products.
  • They have consistently been among the pharma companies in India with the highest investments in research and development.
  • Also, they have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality.
  • Over time, they have emerged as a highly innovative biopharmaceuticals enterprise that has benefited millions of patients in over 120 countries.

BIOCON Ltd – Financial Statements

On the basis of Standalone statement:

Amount (in INR & Lakhs)
30-Sep-19 31-Mar-19 Mar-18 31-Mar-17
Total Assets
*Total Revenue
Total Expense
Profit After Tax

Earnings per Equity Share (in Lakhs)

Amount (in INR & Lakhs)
30-Sep-19 Mar-19 31-Mar-18 31-Mar-17
Basic & Diluted

BIOCON IPO – Promoters

The Promoter of this company is:

  • Kiran Majumdar Shaw

List of Related Parties (Key Managerial Personnel)

  • General Manager (Purchase)
  • Company Secretary and Compliance Officer
  • General Manager (Project)
  • Chief Financial Office

BIOCON IPO Offer Details or Issue Details

Particulars  No. Of Equity Shares
 Equity Shares Offered 
 Of which:
Fresh Issue
Offer for Sale
Of which:

QIB Category 

Of which:
Market Maker Reservation Portion
Net Offer to Public
Of which:
 Equity Shares outstanding prior to the Issue
 Equity Shares outstanding after the Issue

BIOCON IPO Issue Object

  • IPO proceeds to be used for setting up new facilities to augment Submerged Fermentation and Chemical Synthesis capacity.

BIOCON IPO – Basis of the Offer Price

The Offer Price has been determined by their Company and the Selling Shareholder in consultation with the Lead Managers on the basis of the key business strengths.

BIOCON IPO – Quantitative Factors

Basic & Diluted EPS RONW in % NAV (Rs.)
  • Price to Earnings (P/E) ratio in relation to Price band of Rs.[●] of Rs.[●] per each
Particulars P/E ratio

BIOCON Limited: Competitive Peers

Face Value (Rs.) P/E EPS  (Rs.) Return on Net Worth (%) NAV per share (Rs.)
BIOCON Limited
Listed Peers

BIOCON IPO Lead Managers

Lead Managers
DSP Merrill Lynch Ltd.

Kotak Mahindra Capital Company Ltd,

HSBC Securities & Capital Markets (India) Pvt. Ltd

BIOCON IPO Registrar to Offer

Registrar to the Offer

Other Details:

  • Statutory Auditor – [●]
  • Legal Counsel to the Company – [●]
  • Bankers to the Company – [●]

BIOCON IPO Review by Top 10 Stock Brokers

Top Stock Brokers Review Company Reputation Competitive Edge Financial Statement Popularity Index Promoters Reputation
Angel Broking 7.5/10 7.4/10 8.5/10 8.1/10 7.1/10
Sharekhan 7.2/10 7.1/10 8.6/10 8.1/10 7.2/10
Kotak Securities 7.3/10 7.5/10 8.4/10 8.1/10 7.3/10
ICICI Direct 7.3/10 7.3/10 8.7/10 8.1/10 7.1/10
IIFL 7.5/10 7.2/10 8.8/10 8.0/10 7.1/10
Edelweiss 7.5/10 7.4/10 8.4/10 8.3/10 7.2/10
Zerodha 7.4/10 7.1/10 8.5/10 8.1/10 7.0/10
5Paisa 7.1/10 7.1/10 8.4/10 8.1/10 7.1/10
Karvy 7.4/10 7.3/10 8.2/10 8.1/10 7.1/10
Motilal Oswal 7.1/10 7.1/10 8.6/10 8.3/10 7.2/10

BIOCON IPO Grey Market Premium

The BIOCON IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X. 

Subscribe to BIOCON IPO

    Fill Your Details Here
    1. Open Demat AccountInvest in IPO


    News 1BIOCON IPO [Download DRHP Prospectus]

    Market Guide

    Featured Topics

    Get 90% Discount on Brokerage Now! Open Demat Account